Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Novo, however, vastly underestimated the appetite for its new weight-loss jab. Mr Doustdar says it planned for demand to be three times that of Saxenda, an older and less-effective weight-loss drug.

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

The first ‘real-world study’ into the weight loss drug, Mounjaro, has now started in Greater Manchester. Thousands of ...

Eli Lilly will cut prices for its weight loss drug Zepbound, with single-dose vials now available for $299 per month through its LillyDirect platform.

Claudia Oshry got real about her postpartum body. Oshry, 31, took to Instagram on Monday, December 15, to share that she’s ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple ...